{"log_id": 1948309093541876385, "direction": 2, "words_result_num": 29, "words_result": [{"probability": {"variance": 0.000989, "average": 0.98166, "min": 0.833211}, "location": {"width": 874, "top": 1580, "height": 56, "left": 214}, "words": "比安慰剂联合泼尼松治疗的受试者(5%)显著升高,前者约为后者的4.8倍(p=0.0369。所"}, {"probability": {"variance": 0.006504, "average": 0.967385, "min": 0.632411}, "location": {"width": 872, "top": 1534, "height": 59, "left": 214}, "words": "有的缓解均为部分缓解。中国患者的结果与总体人群的结果一致,本品联合泼尼松治疗组和安"}, {"probability": {"variance": 0.01166, "average": 0.953893, "min": 0.448362}, "location": {"width": 626, "top": 1494, "height": 46, "left": 459}, "words": "慰剂联合泼尼松治疗组的客观缓解率分别是32袋和07p=0052"}, {"probability": {"variance": 0.008589, "average": 0.971662, "min": 0.47362}, "location": {"width": 829, "top": 1442, "height": 58, "left": 210}, "words": "安全性结果显示最常报告的不良事件(本品或安慰剂组有≥10%受试者报告)为骨痛、关节"}, {"probability": {"variance": 0.001496, "average": 0.985638, "min": 0.771919}, "location": {"width": 872, "top": 1395, "height": 58, "left": 211}, "words": "痛、背痛、肢端疼痛和高血压。本品组有17%的受试者报告了3或4级不良事件,安慰剂组有"}, {"probability": {"variance": 0.008625, "average": 0.96744, "min": 0.460241}, "location": {"width": 869, "top": 1346, "height": 61, "left": 209}, "words": "2%;两组分别有4%和7%的受试者报告了严重不良事件;分别有3%和4%的受试者报告了导"}, {"probability": {"variance": 0.005725, "average": 0.972393, "min": 0.594896}, "location": {"width": 680, "top": 1299, "height": 53, "left": 399}, "words": "致死亡的不良事件;分别有3%和5%的受试者报告了导致停药的不良事件"}, {"probability": {"variance": 0.006588, "average": 0.976977, "min": 0.505596}, "location": {"width": 829, "top": 1253, "height": 59, "left": 205}, "words": "研究3的结果证实了在未接受过化疗的 MCPC受试者中醋酸阿比特龙联合拨尼松治疗可获"}, {"probability": {"variance": 0.007255, "average": 0.97391, "min": 0.584865}, "location": {"width": 875, "top": 1205, "height": 62, "left": 201}, "words": "得有利的临床获益风险比。本研究中醋酸阿比特龙组的安全性特征与全球关键性批期研究2"}, {"probability": {"variance": 0.000235, "average": 0.991561, "min": 0.944244}, "location": {"width": 342, "top": 1160, "height": 40, "left": 730}, "words": "大体一致。未观察到新的安全性信号"}, {"probability": {"variance": 0.000598, "average": 0.986763, "min": 0.924321}, "location": {"width": 315, "top": 1070, "height": 34, "left": 755}, "words": "中国患者临床试验数据(研究4)"}, {"probability": {"variance": 0.003567, "average": 0.972828, "min": 0.722173}, "location": {"width": 710, "top": 1020, "height": 54, "left": 360}, "words": "既往接受过多西他赛化疗的转移性去势抵抗性前列腺癌者( abi-pro3001)"}, {"probability": {"variance": 0.003817, "average": 0.979221, "min": 0.65983}, "location": {"width": 827, "top": 976, "height": 59, "left": 197}, "words": "中国患者中进行的另一项本品联合泼尼松治疗多西他赛化疗失败的转移性去势抵抗性前列"}, {"probability": {"variance": 0.013553, "average": 0.954243, "min": 0.457938}, "location": {"width": 872, "top": 930, "height": 61, "left": 193}, "words": "腺癌患者的Ⅲ期、随机、双盲、安慰剂对照研究(研究4。所有合格的受试者将在第1周期第"}, {"probability": {"variance": 0.01881, "average": 0.934734, "min": 0.441908}, "location": {"width": 879, "top": 880, "height": 66, "left": 190}, "words": "1天按21的比例随机化分配,分别接受10mg醋酸阿比特龙(以4x250mg片剂给药,每"}, {"probability": {"variance": 0.025971, "average": 0.92763, "min": 0.362843}, "location": {"width": 871, "top": 835, "height": 65, "left": 189}, "words": "日1次)或安慰剂(4片,每日1次),联合泼尼松治疗5mg,每日两次两治疗组间不允"}, {"probability": {"variance": 0.003094, "average": 0.973892, "min": 0.783091}, "location": {"width": 308, "top": 791, "height": 40, "left": 745}, "words": "许交叉。每个治疗周期持续28天"}, {"probability": {"variance": 0.007107, "average": 0.968664, "min": 0.51571}, "location": {"width": 829, "top": 745, "height": 63, "left": 188}, "words": "本研究总计招募并随机化214例受试者。1和安全性分析集均包括醋酸阿比特龙组143"}, {"probability": {"variance": 0.010914, "average": 0.943119, "min": 0.578162}, "location": {"width": 876, "top": 694, "height": 69, "left": 180}, "words": "例受试者和安慰剂维71例受试者。受试接受治疗直至出现疾病进展。疾病进展是指PSA进"}, {"probability": {"variance": 0.017519, "average": 0.935221, "min": 0.459905}, "location": {"width": 872, "top": 651, "height": 66, "left": 181}, "words": "展义前列腺特异性抗原工作组 IPSAWG1标准和影像学进展骨扫描进展或根据改良的实体瘤"}, {"probability": {"variance": 0.028832, "average": 0.91914, "min": 0.403386}, "location": {"width": 874, "top": 605, "height": 66, "left": 177}, "words": "疗效评价标准 REGIST1.】确定的软组织疾病进展伴有或不有临床进展(疼痛进展通过简"}, {"probability": {"variance": 0.011836, "average": 0.955575, "min": 0.478624}, "location": {"width": 872, "top": 559, "height": 67, "left": 177}, "words": "明疼痛调查表-简表 (bpi-sf.评估],出现骨骼相关不良事件,泼尼松剂量增加或换用更强效的糖"}, {"probability": {"variance": 0.008569, "average": 0.962152, "min": 0.601621}, "location": {"width": 871, "top": 514, "height": 65, "left": 174}, "words": "皮质激素,或使用额外的阿片类镇痘剂治疗前列腺癌相关的体征和症状):或临床进展同时伴"}, {"probability": {"variance": 0.003853, "average": 0.9796, "min": 0.71937}, "location": {"width": 389, "top": 470, "height": 42, "left": 655}, "words": "有PSA进展和影像学进展中的一项或两项"}, {"probability": {"variance": 0.008249, "average": 0.969466, "min": 0.487882}, "location": {"width": 834, "top": 423, "height": 64, "left": 168}, "words": "通过测定受试者研究期间的PSA水平评估疗效,主要疗效终点是TPP,定义为从随机化至"}, {"probability": {"variance": 0.011376, "average": 0.954981, "min": 0.49509}, "location": {"width": 845, "top": 373, "height": 65, "left": 187}, "words": "SA进展的时间间隔(根据 PSAWG标准定义:次要疗效终点包括:总生存期、PSA缓解率"}, {"probability": {"variance": 0.025687, "average": 0.914747, "min": 0.416517}, "location": {"width": 877, "top": 329, "height": 67, "left": 161}, "words": "客观缓解率(R)、生活质量(QOL)总评分及前列腺癌治疗功能评价(FACTP)各子量表评"}, {"probability": {"variance": 0.003487, "average": 0.977429, "min": 0.688754}, "location": {"width": 873, "top": 280, "height": 67, "left": 162}, "words": "分、至疼痛进展时间、使用BP-SF最严重疼痛强度评分和止痛药使用评分获得的疼痛缓解的受"}, {"probability": {"variance": 0.005476, "average": 0.970183, "min": 0.62794}, "location": {"width": 542, "top": 236, "height": 48, "left": 490}, "words": "试者比例,以及通过简明疲劳量表(BF)评估的疲劳程度"}], "language": 3}